Meeting
2024 ASCO Genitourinary Cancers Symposium
Predicting efficacy in patients with locally advanced (LA)/metastatic urothelial carcinoma (mUC) treated with avelumab using machine learning and explainability approaches.
Authors
Patrizia Giannatempo
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
Patrizia Giannatempo , Vanja Miskovic , Matteo Piceni , Elisabetta Gambale , Marco Stellato , Achille Bottiglieri , Ferrari Bravo Walter , Simone Oldani , Marco Maruzzo , Davide Bimbatti , Alessia Mennitto , Sara Elena Rebuzzi , Chiara Mercinelli , Mariella Sorarù , Luca Galli , Carlo Messina , Roberto Iacovelli , Lorenzo Antonuzzo , Arsela Prelaj , Giuseppe Procopio
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 688)
DOI
10.1200/JCO.2024.42.4_suppl.688
Abstract #
688
Poster Bd #
L10
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Real-world treatment patterns and sequencing in patients with locally advanced or metastatic urothelial cancer (la/mUC) in the US.
First Author: Mairead Kearney
Poster
2022 ASCO Annual Meeting
Phase Ib study of avelumab and novel AXL inhibitor avb-S6-500 in patients with metastatic urothelial carcinoma (mUC).
First Author: Abhishek Tripathi
First Author: Igor Tsaur
Poster
2024 ASCO Annual Meeting
Clinical outcomes of sacituzumab govitecan (SG) after prior exposure to enfortumab vedotin (EV) in patients with metastatic urothelial carcinoma (mUC).
First Author: Michal Sternschuss